Best VJHemOnc Podcasts (2025)

1
Highlights from EBMT 2025: preventing and managing GvHD, harnessing AI in transplant, & more 22:53

6d ago22:53

22:53

In this week’s VJHemOnc podcast, we’ll be sharing highlights from the 51st Annual Meeting of the EBMT, with a focus on the prevention and management of graft-versus-host disease (GvHD) and infections associated with stem cell transplantation (SCT). You will also hear about the potential of artificial intelligence (AI) in hematology and transplantat…

1
Sequencing therapies in R/R NHL: immunotherapy in DLBCL, BTKis in MCL, & more! 46:21

9d ago46:21

46:21

This podcast episode features experts Paolo Strati, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Gloria Iacoboni, MD, PhD, Vall d’Hebron Institute of Oncology, Barcelona, Spain, and Manali Kamdar, MD, University of Colorado Cancer Center, Denver, CO, who discuss the sequencing of therapies in relapsed/refractory (R/R) non-Hod…

1
Novel CAR strategies being explored in lymphoma: allogeneic products, trispecific CARs & new manufacturing platforms 18:06

23d ago18:06

18:06

CAR T-cell therapy has revolutionized the lymphoma treatment landscape in recent years. In this episode, we delve into cutting-edge CAR strategies being investigated for lymphoma, including allogeneic products, trispecific CARs, and more. Key highlights include insights into CTX112, a next-generation allogeneic CRISPR-Cas9 engineered CD19 CAR T-cel…

1
Approaches to optimizing induction therapy in AML: FLT3 inhibitors, menin inhibitors, CPX-351, & more! 23:26

26d ago23:26

23:26

Newly diagnosed acute myeloid leukemia (AML) is traditionally treated with intensive chemotherapy for eligible patients, but ongoing research is exploring the addition of targeted agents. This podcast focuses on approaches being explored to optimize induction therapy in AML, featuring experts Tapan Kadia, MD, The University of Texas MD Anderson Can…

1
Treating R/R mantle cell lymphoma: the role of BTK inhibitors, combination approaches being explored & overcoming resistance 16:52

1M ago16:52

16:52

BTK inhibitors have transformed the treatment landscape in both frontline and relapsed/refractory (R/R) mantle cell lymphoma (MCL), offering a targeted therapy option for patients. In this podcast, you will hear from Krish Patel, MD, Sarah Cannon Cancer Institute, Nashville, TN, Yucai Wang, MD, PhD, Mayo Clinic, Rochester, MN, Julie Vose, MD, Unive…

1
Addressing unmet needs in myeloma: early detection, frail/elderly patients, triple-class exposed disease, & more! 27:48

1M ago27:48

27:48

In recognition of Myeloma Awareness Month 2025, this podcast explores key unmet needs and unanswered questions in myeloma research and patient care, offering insights and strategies for healthcare professionals to address them. The discussion centers on four topics: the treatment of smoldering myeloma, managing frail and elderly patients, challenge…

1
CAR T-cell therapy in ALL: trial updates, novel approaches, & real-world outcomes 18:39

2M ago18:39

18:39

CAR T-cell therapy has become an established treatment for several hematological malignancies, including acute lymphoblastic leukemia (ALL), and has significantly changed the therapeutic landscape for patients. In this podcast episode, renowned experts will share insight into the use of CAR-T in ALL, including updates of pivotal trials, novel appro…

1
Post-ASH amyloidosis highlights: the ANDROMEDA trial, risk stratification, value of MRD, & more! 13:15

2M ago13:15

13:15

Today's podcast features a discussion with experts Vaishali Sanchorawala, MD, Boston University School of Medicine, Boston, MA, and Ashutosh Wechalekar, MBBS, MD, FRCP, FRCPath, DM, University College London Hospitals NHS Foundation Trust, London, UK, from the 66th ASH Annual Meeting and Exposition. They share their key highlights in amyloidosis fr…

1
Post-ASH non-malignant highlights: updates in sickle cell disease, thalassemia, and hemophilia 18:27

2M ago18:27

18:27

This episode of the VJHemOnc podcast covers updates in non-malignant hematological diseases from the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, which took place in San Diego, CA. You will hear the latest updates in sickle cell disease (SCD), thalassemia, and hemophilia from leading experts. First, Sophia Delicou, MD, H…

1
Post-ASH myeloma highlights: key takeaways for community physicians & trials to look out for in 2025 18:29

3M ago18:29

18:29

This podcast brings you exclusive updates on multiple myeloma from the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, held in San Diego, CA. In this episode, experts Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, Rahul Banerjee, MD, FACP, Fred Hutchinson Cancer Cen…

1
Post-ASH AML highlights: novel approaches to frontline therapy, advances with menin inhibitors, & managing FLT3-ITD+ AML 28:59

3M ago28:59

28:59

In this podcast, we bring you exclusive updates on acute myeloid leukemia (AML) from the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, which took place in San Diego, CA. You will hear insights into novel approaches to frontline chemotherapy and BCL2 inhibition from experts Ioannis Mantzaris, MD, Montefiore Medical Center/…

1
Post-ASH MPN highlights: key trial updates in MF, novel approaches being explored in R/R disease, & more! 22:21

3M ago22:21

22:21

This podcast episode covers key highlights in myeloproliferative neoplasms (MPNs) from the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, which took place in San Diego, CA. First, you will hear key trial updates in myelofibrosis (MF) from Andrew Kuykendall, MD, Moffitt Cancer Center, Tampa, FL, Lucia Masarova, MD, The Univ…

1
Post-ASH NHL highlights: novel combinations in the frontline setting and advancements with immunotherapy in the R/R setting 31:20

3M ago31:20

31:20

Today's podcast showcases key updates in non-Hodgkin lymphoma (NHL) from the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, which took place in San Diego, CA. First, you will hear from Gilles Salles, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, Catherine Diefenbach, MD, NYU Langone, New York, NY, and Jia …

1
Post-ASH MDS highlights: managing anemia in LR-MDS and novel approaches to treating HR-MDS 19:02

3M ago19:02

19:02

This podcast is the second episode in our series spotlighting key highlights from the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, which took place in San Diego, CA. This episode focuses on updates in myelodysplastic syndromes (MDS). You will hear insights into managing anemia in lower-risk MDS (LR-MDS) from Sophie Park,…

1
Post-ASH CLL highlights: BTK inhibitors & degraders, bispecific antibodies, & more! 16:31

3M ago16:31

16:31

VJHemOnc recently attended the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, CA, where we gained expert insights into cutting-edge research in hematological malignancies. This podcast series will cover highlights in a variety of disease areas. Today's episode focuses on chronic lymphocytic leukemia (CLL). You…

1
Advancing treatment for BPDCN: current therapies, a deep dive into tagraxofusp, & emerging novel agents 28:52

4M ago28:52

28:52

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy characterized by involvement of the skin, bone marrow, and lymph nodes, often associated with a poor prognosis. In this podcast episode, Naveen Pemmaraju, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, provides an in-depth explo…

1
Improving care for patients with SCD: pain management, ongoing projects & unmet needs 16:45

5M ago16:45

16:45

This week's podcast focuses on strategies to improve care for patients with sickle cell disease (SCD), featuring expert insights from the 19th Annual Scientific Conference on Sickle Cell and Thalassemia (ASCAT 2024), which was held in London, UK. You will hear from Natasha Archer, MD, MPH, Harvard Medical School, Boston, MA, Subarna Chakravorty, MB…

1
Understanding BPDCN: dermatology and hematology perspectives on presentation, diagnosis, treatment, & multidisciplinary care 34:43

5M ago34:43

34:43

In this podcast, experts Marlise Luskin, MD, MSCE, Dana-Farber Cancer Institute, Boston, MA, Nicole LeBoeuf, MD, MPH, Dana-Farber Cancer Institute, Boston, MA, and Shai Shimony, MD, Dana-Farber Cancer Institute, Boston, MA, share insights into the clinical presentation, diagnosis, and treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN…

1
Managing complications associated with WM: Bing-Neel syndrome, acquired von Willebrand disease, & more! 21:36

5M ago21:36

21:36

Today's podcast episode focuses on the management of complications associated with Waldenström's macroglobulinemia (WM), featuring expert insights from the 12th International Workshop on Waldenström's Macroglobulinemia (IWWM-12) held in Prague, Czech Republic. You will hear from Shirley D’Sa, MD, FRCP, FRCPath, University College London, London, UK…

1
CAR-T therapies and bispecific antibodies in the treatment of high-risk multiple myeloma: updates from iwHRMM 2024 24:59

5M ago24:59

24:59

This week's podcast features discussions on the use of immunotherapy in the treatment of high-risk multiple myeloma (HRMM) from the 1st International Workshop on High-Risk Multiple Myeloma (iwHRMM), which took place Charleston, SC. You will hear from experts Ajai Chari, MD, University of California San Francisco, San Francisco, CA, and Krina Patel,…

1
The treatment landscape and challenges in rare diseases: BPDCN, CMML, MPN-AP/BP, and VEXAS 22:39

6M ago22:39

22:39

This podcast features a discussion from the 6th International Workshop on Acute Leukemias (iwAL) 2024, which took place in Phoenix, AZ. You will hear from Anand Patel, MD, University of Chicago Medical Center, Chicago, IL, Marina Konopleva, MD, PhD, Albert Einstein College of Medicine, New York City, NY, Guillermo Montalban-Bravo, MD, The Universit…

1
Exploring the role of BTK inhibitors in mantle cell lymphoma: sequencing & managing adverse events 9:29

6M ago9:29

9:29

Today's podcast focuses on the role of BTK inhibitors (BTKis) in the treatment of mantle cell lymphoma (MCL). You will hear from experts Krish Patel, MD, Providence Swedish Cancer Institute, Seattle, WA, Marek Trněný, MD, PhD, Charles University Hospital, Prague, Czech Republic, Michael Wang, MD, The University of Texas MD Anderson Cancer Center, H…

1
An update on menin inhibition in AML from iwAL 2024: current data, mechanisms of resistance, & more! 16:34

6M ago16:34

16:34

Menin inhibitors are emerging as a promising therapeutic approach in acute myeloid leukemia (AML), particularly in patients with specific genetic mutations such as KMT2A-rearranged and NPM1-mutated AML. These inhibitors disrupt the leukemogenic signaling pathways that drive leukemia cell proliferation by blocking the actions of menin. They can help…

1
CAR T-cells and bispecific antibodies in the treatment of NHL: updates from iwNHL 2024 20:30

6M ago20:30

20:30

Today's podcast features discussions from the 21st International Workshop on Non-Hodgkin Lymphoma (iwNHL) which took place in Nice, France. You will hear updates on the use of CAR T-cell therapy in non-Hodgkin lymphoma (NHL) from experts Catherine Bollard, MBChB, MD, FRACP, FRCPA, Children’s National Health System, Washington, DC, Stephen Schuster,…

1
Prolonging remission in AML: current approaches & future outlooks 31:27

7M ago31:27

31:27

Today's podcast features a discussion with leading experts Harry Erba, MD, PhD, Duke University, Durham, NC, Farhad Ravandi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, and Thomas Cluzeau, MD, PhD, Central University Hospital of Nice, Nice, France, on strategies to prolong remission in acute myeloid leukemia (AML). They focu…

1
A focus on the use of artificial intelligence to personalize blood cancer care 28:55

7M ago28:55

28:55

Welcome to the final episode of VJHemOnc's Blood Cancer Awareness Month special series! This episode focuses on the role of artificial intelligence (AI) in personalizing blood cancer care. Carsten Niemann, MD, PhD, Copenhagen University Hospital, Copenhagen, Denmark, discusses the value of AI in hematological oncology and how it is currently used i…

1
A focus on pediatric leukemias: trials, treatments, & challenges 17:44

7M ago17:44

17:44

Welcome to the third episode of VJHemOnc’s Blood Cancer Awareness Month special series! The focus of this episode is pediatric acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). You will hear from Michele Redell, MD, Texas Children’s Cancer Center, Baylor College of Medicine, Houston, TX, who shares insights into the Pediatric Acu…

1
A focus on the psychosocial impacts of living with blood cancer 36:22

7M ago36:22

36:22

Welcome to the second episode of VJHemOnc’s Blood Cancer Awareness Month special series! Today's episode focuses on the psychosocial impacts of living with blood cancer. First, you will hear from Lorna Warwick, BA, Lymphoma Coalition, Toronto, Canada, who shares the work of the Lymphoma Coalition Global Patient Survey. Next, you will hear insights …

1
Global perspectives on blood cancers: addressing disparities in awareness, diagnosis, and treatment 18:54

8M ago18:54

18:54

Welcome to the first episode of VJHemOnc's Blood Cancer Awareness Month special series! This episode focuses on global perspectives of blood cancers and addresses the disparities that exist in awareness, diagnosis, and treatment. First, Lalit Kumar, MD, MBBS, Artemis Hospital, New Delhi, India, discusses challenges that exist in the management of b…

1
Insights into PV and ET: treating the AYA population, defining goals when treating patients, & more 11:50

8M ago11:50

11:50

Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms (MPNs) characterized by the overproduction of red blood cells and platelets, respectively, due to mutations in hematopoietic stem cells. In this podcast, experts Andrew Kuykendall, MD, Moffitt Cancer Center, Tampa, FL; Lucia Masarova, MD, The University of Te…

1
Hemophilia updates from ISTH 2024: ongoing clinical trials, emerging gene therapies & remaining challenges 18:41

8M ago18:41

18:41

This week's VJHemOnc podcast brings you updates in hemophilia from the 32nd Congress of the International Society on Thrombosis and Haemostasis (ISTH), held in Bangkok, Thailand, and virtually. You hear from experts Omolade Awodu, MBChB, MD, FMCPath, University of Benin, Benin City, Nigeria, who discusses key hemophilia clinical trials in 2024, Rad…

1
Inflammation and immune interventions in MDS: targeting STAT, IRAK4, & more 17:29

8M ago17:29

17:29

In myelodysplastic syndromes (MDS), chronic inflammation driven by the innate immune system plays a key role in disease progression. Signal Transducer and Activator of Transcription (STAT) and Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) are critical mediators in this process, where dysregulated signaling leads to aberrant hematopoiesis and t…

1
Updates in the treatment of SCD and thalassemia from EHA 2024: key trial updates, challenges with gene therapies & unmet needs 11:58

9M ago11:58

11:58

Today’s VJHemOnc podcast features experts Rabi Hanna, MD, The Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, Subarna Chakravorty, MBBS, MRCPCH, FRCPath, PhD, King’s College Hospital NHS Foundation Trust, London, UK, and Ali Taher, MD, PhD, FRCP, American University of Beirut Medical Center, Beirut, Lebanon. They discuss key updates in si…

1
Unmet treatment needs in MF: managing prefibrotic disease & thrombocytopenia, novel agents & endpoints for clinical trials 16:00

9M ago16:00

16:00

Myelofibrosis (MF) is a chronic myeloproliferative neoplasm (MPN) characterized by bone marrow fibrosis, extramedullary hematopoiesis, and splenomegaly, often resulting in anemia and thrombocytopenia. There are many unmet treatment needs that remain in this space. This week’s podcast features a discussion from the International Workshop on Myelodys…

1
The role of BTK inhibitors in MCL, ongoing trials & future outlooks: updates from EHA 2024 12:13

9M ago12:13

12:13

The introduction of Bruton's tyrosine kinase (BTK) inhibitors into the treatment landscape for mantle cell lymphoma (MCL) has transformed the field and provided patients with a promising therapeutic option. In this podcast, you will hear from leading experts who discuss the value of these agents in MCL, sharing updates from EHA 2024. Tune in as Man…

1
Novel developments in lower-risk MDS & important practical considerations when treating patients 51:42

9M ago51:42

51:42

In today’s VJHemOnc podcast, we will be sharing novel developments in lower-risk myelodysplastic syndromes (LR-MDS) and important practical considerations when treating patients. You will hear from experts Amer Zeidan, MBBS, Yale University and Yale Cancer Center, New Haven, CT, Rena Buckstein, MD, FRCPC, Odette Cancer Research Program, Sunnybrook …

1
Updates on the use of BCMA-targeting bispecific antibodies in R/R multiple myeloma: insights from EHA & ASCO 2024 16:18

10M ago16:18

16:18

BCMA-targeting bispecific antibodies treat multiple myeloma by binding to BCMA on malignant plasma cells and directing T-cells to initiate targeted cell killing. This podcast provides updates on the use of BCMA-targeting bispecific antibodies in relapsed/refractory (R/R) multiple myeloma from the 2024 American Society of Clinical Oncology (ASCO) Me…

1
Updates in the treatment of CLL from EHA 2024: BTK and BCL2 inhibitor combinations, BTK degraders, and more 12:10

10M ago12:10

12:10

In today's VJHemOnc podcast, we will be sharing key updates in the treatment of chronic lymphocytic leukemia (CLL) and Richter’s transformation (RT) from the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain. You will hear from experts Toby Eyre, MBChB (Hons), DipMedEd, MRCP (UK), FRCPath (UK), MD, Oxford University Hospit…

1
Highlights from ISA 2024: the importance of early diagnosis in AL amyloidosis, trials in progress & patient selection for SCT 8:43

10M ago8:43

8:43

Welcome to today's VJHemOnc podcast episode, where we will be sharing key highlights from the 2024 International Symposium on Amyloidosis (ISA), which was held in Rochester, MN. This podcast covers a variety of unmet needs in light chain (AL) amyloidosis, as well as emerging trials in the field. Join leading experts Mario Nuvolone, MD, PhD, Univers…

1
Treating LR-MDS beyond ESA failure: currently approved agents, novel approaches & future outlooks 46:31

11M ago46:31

46:31

While there have been advances in the treatment of lower-risk myelodysplastic syndromes (LR-MDS) in recent years, one major challenge that remains is the treatment of patients following the failure of erythropoiesis-stimulating agents (ESAs). In this podcast, experts Amer Zeidan, MBBS, Yale Cancer Center, New Haven, CT, Valeria Santini, MD, Univers…

1
BPDCN treatment and management: CD123-targeting agents, CNS involvement & approaching pediatric/AYA patients 34:39

11M ago34:39

34:39

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive hematologic malignancy originating from plasmacytoid dendritic cells, characterized by skin lesions and frequent involvement of bone marrow and lymphoid tissues. Patients have a poor prognosis, making early diagnosis and advanced treatments, including targeted therapies, crucial …

1
The future of CAR-T therapy in lymphoma, addressing the risk of secondary malignancy & the optimal sequencing of these agents with bispecific antibodies 12:34

11M ago12:34

12:34

Immunotherapeutic approaches, including CAR T-cells and bispecific antibodies, have become well-established in later lines of non-Hodgkin lymphoma (NHL) treatment. CAR T-cells are engineered to target specific antigens expressed on lymphoma cells, and bispecific antibodies simultaneously bind to both tumor cells and immune cells, enhancing the immu…

1
iwMyeloma 2024 Session I: approaching bone disease, clinical trial updates & the value of MRD as an endpoint in trials 27:24

12M ago27:24

27:24

The 17th International Workshop on Multiple Myeloma (iwMyeloma 2024) was held recently in Miami, FL, and brought together experts from around the world to discuss the latest updates, challenges, and research in the field. In this episode, Ola Landgren, MD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, Suzanne Lentzsch, MD, …

1
Managing anemia in MF, key emerging trials in the UK, and approaching young patients with MPNs 11:43

12M ago11:43

11:43

Myelofibrosis (MF) is a hematologic malignancy that causes progressive bone marrow fibrosis and presents with other clinical manifestations, including anemia and splenomegaly. MF-related anemia can be challenging to manage, and strategies are being explored to improve outcomes for patients. Today's VJHemOnc podcast features experts Mary Frances McM…

1
Highlights from EBMT 2024: treating & managing GvHD & understanding the role of the gut microbiome 22:50

12M ago22:50

22:50

Graft-versus-host disease (GvHD) is a common complication following allogeneic stem cell transplantation (alloSCT), which is typically classified as acute or chronic. In this week's VJHemOnc podcast, we'll be sharing key highlights from the 50th Annual Meeting of the EBMT, drawing focus on the biology and treatment of GvHD. Tune in as experts Moham…

1
The importance of cardio-oncology: awareness around the ESC 2022 guidelines & the value of building MDTs 43:51

1y ago43:51

43:51

In recent years, there has been great emphasis placed on the importance of cardio-oncology, with both cardiologists and hematologists highlighting the value of collaboration between specialists when treating patients with hematological malignancies. Furthermore, the 2022 European Society of Cardiology (ESC) cardio-oncology guidelines aim to help he…

1
Exploring the possibility of early interception in smoldering myeloma: novel agents, challenges & advances in risk stratification 22:22

1y ago22:22

22:22

Smoldering multiple myeloma (SMM) and monoclonal gammopathy of undetermined significance (MGUS) are two well-known precursor conditions to multiple myeloma, and the possibility of early interception is a growing area of interest in the field. In this week's podcast, you will hear from Shaji Kumar, MD, Mayo Clinic, Rochester, MN, Elena Zamagni, MD, …

1
CHIP & CCUS: knowledge gaps, ongoing trials & recommendations for approaching patients with myeloid precursors 13:02

1y ago13:02

13:02

Clonal hematopoiesis of indeterminate potential (CHIP) and clonal cytopenia of unknown significance (CCUS) are considered precursor diseases to hematologic malignancies, indicating early stages of blood disorders that may progress to more serious conditions such as leukemia or myelodysplastic syndromes (MDS). In this podcast, Uma Borate, MD, The Oh…

1
Monoclonal B-cell lymphocytosis: classification, biology and exploring the possibility of early interception 9:39

1y ago9:39

9:39

Monoclonal B-cell lymphocytosis (MBL) is a condition characterized by the presence of an abnormal increase in B lymphocytes in the blood. MBL is considered a precursor condition to chronic lymphocytic leukemia (CLL); however, not all cases of MBL progress to CLL, and many individuals with MBL do not require treatment. In this podcast, Stephen Ansel…

1
The impact of CAR-T therapy on the myeloma treatment landscape, patient selection for CAR-T & the evolving role of autoSCT 13:00

1y ago13:00

13:00

The introduction of CAR-T therapy has revolutionized the myeloma treatment landscape, offering a promising therapeutic approach for patients with relapsed/refractory (R/R) disease. There are currently two approved CAR-T cells in multiple myeloma: idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), with ongoing studies explor…

Podcasts Worth a Listen

VJHemOnc Podcasts

Podcasts Worth a Listen

Quick Reference Guide

zproxy.org